BETHESDA, Md., May 20, 2013 /PRNewswire/ -- TNI BioTech, Inc. (OTCQB: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using patented immunotherapy, announced its common stock is trading on the OTC Markets' OTCQB marketplace under the ticker symbol "TNIB" commencing May 17, 2013. Investors will be able to view the real-time Level II stock quotes for TNIB at http://www.otcmarkets.com/stock/TNIB/quote.
Noreen Griffin , CEO of TNI BioTech, Inc. stated, "We are very pleased to provide this additional trading venue to further enhance liquidity, particularly for our current and future shareholders."
The transition to the OTCQB does not change TNI BioTech's reporting obligations with the Securities and Exchange Commission (SEC) under applicable federal securities laws. The company intends to continue to file its quarterly reports on Form 10-Q, annual report on Form 10-K and current reports on Form 8-K. The company anticipates the timely reporting of its second fiscal quarter ending June 30, 2013 on or before August 14, 2013.
About TNI BioTech, Inc.
TNI BioTech, Inc. is a biotech company with the goal of benefitting patients with chronic and often life-threatening diseases through the activation and rebalancing of the body's immune system, using our patented immunotherapy.
Our products, technologies and patents are designed to harness the power of the immune system to improve the treatment of cancer, chronic infections such as HIV/AIDS, and autoimmune diseases and, such as Crohn's disease, other types of inflammatory bowel disease, and multiple sclerosis.
Our most advanced clinical programs involve immunotherapy with methionine-enkephalin (MENK) or low dose naltrexone, which both work by triggering opioid receptors on immun
|SOURCE TNI BioTech, Inc.|
Copyright©2012 PR Newswire.
All rights reserved